{"doi":"10.1111/bjh.19978","title":"Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse","abstract":"<jats:title>Summary</jats:title>\n                  <jats:p>Most transplant‐ineligible patients present with multiple myeloma (MM) refractory to lenalidomide and/or anti‐CD38 monoclonal antibody at first relapse and represent a difficult‐to‐treat population. The Intergroupe Francophone du Myélome phase 2 study iberdomide, ixazomib and dexamethasone (I2D) evaluated the oral triplet iberdomide, ixazomib and dexamethasone in MM patients aged ≥70 years at first relapse (NCT04998786). Seventy patients were enrolled to receive iberdomide (1.6 mg on day 1–21), ixazomib (3 mg on day 1, 8, 15) and dexamethasone (20 mg on day 1, 8, 15, 22 on cycle 1–2 and 10 mg on day 1, 8, 15, 22 on cycle 3–6) (28‐day cycle) until disease progression. Median age was 76; 50% patients were frail according to the International Myeloma Working Group frailty score; 74% and 37% were refractory to lenalidomide and daratumumab respectively. With a median follow‐up of 14 months, the overall response rate was 64%, including 36% very good partial response or better. The 12‐month progression‐free survival, duration of response and overall survival were 52%, 76% and 86% respectively. The most common (46%) grade 3–4 toxicity was neutropenia. Non‐haematological adverse events were mostly grade 1 or 2. Overall, I2D demonstrated a favourable risk–benefit profile in elderly MM patients at first relapse, including in patients with lenalidomide and daratumumab refractory disease.</jats:p>","journal":"British Journal of Haematology","year":2025,"id":646227,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":683470,"name":"Xavier Leleu","orcid":"0000-0002-9822-4170","position":1,"is_corresponding":false},{"id":684191,"name":"Mourad Tiab","orcid":null,"position":2,"is_corresponding":false},{"id":683471,"name":"Margaret Macro","orcid":"0000-0002-0460-0658","position":3,"is_corresponding":false},{"id":683467,"name":"Aurore Perrot","orcid":"0000-0003-0131-8689","position":4,"is_corresponding":false},{"id":1619877,"name":"Julie Gay","orcid":null,"position":5,"is_corresponding":false},{"id":1683060,"name":"Carine Chateleix","orcid":null,"position":6,"is_corresponding":false},{"id":1665079,"name":"Stéphane Moreau","orcid":null,"position":7,"is_corresponding":false},{"id":642049,"name":"Lionel Karlin","orcid":"0000-0002-1185-4488","position":8,"is_corresponding":false},{"id":1047113,"name":"Caroline Jacquet","orcid":null,"position":9,"is_corresponding":false},{"id":250472,"name":"Salomon Manier","orcid":"0000-0001-7653-711X","position":10,"is_corresponding":false},{"id":683468,"name":"Cyrille Hulin","orcid":"0000-0002-3749-5161","position":11,"is_corresponding":false},{"id":1622189,"name":"Olivier Decaux","orcid":null,"position":12,"is_corresponding":false},{"id":683474,"name":"Valentine Richez","orcid":"0000-0002-1356-9613","position":13,"is_corresponding":false},{"id":1046730,"name":"Thomas Chalopin","orcid":"0000-0002-9833-3115","position":14,"is_corresponding":false},{"id":318414,"name":"Mohamad Mohty","orcid":"0000-0002-7264-808X","position":15,"is_corresponding":false},{"id":869245,"name":"Frédérique Orsini‐Piocelle","orcid":null,"position":16,"is_corresponding":false},{"id":683469,"name":"Denis Caillot","orcid":"0009-0009-6985-5609","position":17,"is_corresponding":false},{"id":1683061,"name":"Cécile Sonntag","orcid":null,"position":18,"is_corresponding":false},{"id":1683062,"name":"Marguerite Vignon","orcid":null,"position":19,"is_corresponding":false},{"id":1683063,"name":"Arthur Bobin","orcid":null,"position":20,"is_corresponding":false},{"id":228855,"name":"Hervé Avet‐Loiseau","orcid":"0000-0002-3050-0140","position":21,"is_corresponding":false},{"id":1683064,"name":"Alexandra Jobert","orcid":"0000-0001-9117-0934","position":22,"is_corresponding":false},{"id":1683065,"name":"Lucie Planche","orcid":null,"position":23,"is_corresponding":false},{"id":683466,"name":"Jill Corre","orcid":"0000-0003-1580-6106","position":24,"is_corresponding":false},{"id":229121,"name":"Philippe Moreau","orcid":"0000-0003-1780-8746","position":25,"is_corresponding":false},{"id":1360962,"name":"Cyrille Touzeau","orcid":"0000-0003-0275-2575","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse","abstract":"<jats:title>Summary</jats:title>\n                  <jats:p>Most transplant‐ineligible patients present with multiple myeloma (MM) refractory to lenalidomide and/or anti‐CD38 monoclonal antibody at first relapse and represent a difficult‐to‐treat population. The Intergroupe Francophone du Myélome phase 2 study iberdomide, ixazomib and dexamethasone (I2D) evaluated the oral triplet iberdomide, ixazomib and dexamethasone in MM patients aged ≥70 years at first relapse (NCT04998786). Seventy patients were enrolled to receive iberdomide (1.6 mg on day 1–21), ixazomib (3 mg on day 1, 8, 15) and dexamethasone (20 mg on day 1, 8, 15, 22 on cycle 1–2 and 10 mg on day 1, 8, 15, 22 on cycle 3–6) (28‐day cycle) until disease progression. Median age was 76; 50% patients were frail according to the International Myeloma Working Group frailty score; 74% and 37% were refractory to lenalidomide and daratumumab respectively. With a median follow‐up of 14 months, the overall response rate was 64%, including 36% very good partial response or better. The 12‐month progression‐free survival, duration of response and overall survival were 52%, 76% and 86% respectively. The most common (46%) grade 3–4 toxicity was neutropenia. Non‐haematological adverse events were mostly grade 1 or 2. Overall, I2D demonstrated a favourable risk–benefit profile in elderly MM patients at first relapse, including in patients with lenalidomide and daratumumab refractory disease.</jats:p>","is_dataset_classified":null,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39757748","pmcid":null,"openalex_id":"https://openalex.org/W4406108786","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P01 CA155258","title":null},{"funder_name":"Takeda Pharmaceutical Company","grant_id":"","title":null},{"funder_name":"Bristol Myers Squibb Foundation","grant_id":"","title":null},{"funder_name":"Bristol Myers Squibb Foundation","grant_id":"","title":null},{"funder_name":"Takeda Pharmaceutical Company","grant_id":"","title":null}],"total_grants":5,"fwci":5.8239,"citation_percentile":0.95981994,"influential_citations":0,"citation_trend":[{"year":2025,"count":3},{"year":2026,"count":4}],"oa_status":"bronze","license":"cc-by","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.19978","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.19978","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19978","host_type":"publisher"},{"url":"https://doi.org/10.1111/bjh.19978","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39757748","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13334503/","host_type":"repository"}],"fields_of_study":["Multiple Myeloma Research and Treatments","Protein Degradation and Inhibitors","Myeloproliferative Neoplasms: Diagnosis and Treatment","Humans","Multiple Myeloma","Boron Compounds","Aged","Glycine","Dexamethasone","Male","Female","Antineoplastic Combined Chemotherapy Protocols","Aged, 80 and over","Thalidomide","Recurrence"],"mesh_terms":["Aged","Aged, 80 and over","Antineoplastic Combined Chemotherapy Protocols","Boron Compounds","Dexamethasone","Female","Glycine","Humans","Male","Multiple Myeloma","Recurrence","Thalidomide"],"keywords":["Ixazomib","Dexamethasone","Multiple myeloma","Medicine","Oncology","Internal medicine","Lenalidomide","Carfilzomib","Elderly","myeloma","Iberdomide"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T12:15:36.326041Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}